digital health investment

Alexandre Momeni, a partner at General Catalyst, describes how the VC firm funds visionary founders building frontier technologies while balancing high-risk bets with responsible innovation and strategic portfolio construction.

The company will grow its clinical team and expand its offerings across GI partner clinics representing 700 physicians, after an 800% rise in patient volume.

The funds will be used to help the company expand into the employer and health plan markets and speed up the development of its AI technology for providers and members.

The company uses AI and ML to assist biopharma companies with clinical trials and will use the funds to expand its precision medicine and clinical development tools.

Epicore Biosystems expands Series B to $32 million to advance sweat-sensing wearable technology.

The company will fund and develop companies that focus on eight key areas in healthcare and create AI/genAI technologies that help advance those areas.

OneCell Diagnostics scores $16 million for genomics-based precision oncology and dannce.ai, a phenotyping platform to digitize clinical assessments, secures $2.6 million.

The funding includes $4.5 billion for the firm's core VC funds, $1.5 billion for its Creation strategy and $2 billion for separately managed accounts.

The company will use the funds to launch its diagnostics division and expand its offerings under the helm of its new chief operating officer.

Ben Robbins, general partner at GV, wraps up MobiHealthNews' investment series by unveiling the crucial traits digital health companies must possess to secure funding in a highly competitive market.